Current Value
$0.241 Year Return
Current Value
$0.241 Year Return
Yahoo
Multi-pronged media campaign to raise awareness about the disease and its impact on patients, family members and caregivers.Interactive, stand-alone NETHERTON NOW website launched.Quoin’s QRX003 product is on track to obtain the first regulatory approval for Netherton Syndrome. ASHBURN, Va., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, has launched the
Yahoo
The recent 13% drop in Quoin Pharmaceuticals, Ltd.'s ( NASDAQ:QNRX ) stock could come as a blow to insiders who...
Yahoo
Four Weeks After Discontinuation of Treatment with QRX003 Complete Reversal of Positive Clinical Improvements Across all Measured Endpoints ObservedData Supports QRX003 Mechanism of Action as a Competitive Broad Spectrum Serine Protease Inhibitor ASHBURN, Va., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today announces further clinical evidence of th
Yahoo
Skinvisible Pharmaceuticals, Inc. ("Skinvisible" or "the Company"), (OTCQB:SKVI), an innovative topical and transdermal pharmaceutical research and development company, with proprietary Invisicare® drug delivery technology, today announces significant ...
Yahoo
Continued Significant Improvement in Skin Appearance Observed in StudySubject’s Disease Classification Improved from “Severe” to “Mild” after 6 Weeks Dosing Treatment area expanded from 20% Body Surface Area to “Whole Body” ASHBURN, Va., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today announces positive interim clinical data from its ongoing Invest
Yahoo
Published Before-and-After Photos Highlight Dramatic Improvements in Netherton Syndrome Patient Treated with QRX003NEW YORK, Jan. 07, 2025 (GLOBE NEWSWIRE) -- PRISM MarketView has released an exclusive interview with Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) CEO Dr. Michael Myers, who shares the company’s notable interim data in its ongoing Netherton Syndrome clinical trials. Quoin, a clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, is addressing unmet medical
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
FLOT | -20.38% | $8.97B | 0.15% |
BTAL | -10.74% | $404.97M | 1.43% |
FLRN | -10.50% | $2.82B | 0.15% |
FLTR | -9.71% | $2.42B | 0.14% |
BOXX | -9.16% | $5.72B | 0.1949% |
DBA | -9.00% | $822.16M | 0.93% |
CANE | -8.57% | $11.05M | 0.29% |
BIL | -7.97% | $41.08B | 0.1356% |
TPMN | -7.32% | $33.51M | 0.65% |
ICLO | -6.58% | $354.53M | 0.2% |
CLOA | -6.27% | $786.72M | 0.2% |
UUP | -5.92% | $327.80M | 0.77% |
CTA | -5.67% | $963.19M | 0.76% |
USDU | -5.47% | $213.46M | 0.5% |
TAIL | -5.20% | $86.92M | 0.59% |
BILZ | -5.00% | $709.48M | 0.14% |
UNG | -4.92% | $434.44M | 1.06% |
DRLL | -4.91% | $299.17M | 0.41% |
IEO | -4.91% | $559.60M | 0.4% |
XBIL | -4.86% | $708.45M | 0.15% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
PBJ | -0.06% | $92.06M | 0.62% |
VNM | 0.06% | $416.76M | 0.7% |
IYH | 0.06% | $3.18B | 0.39% |
CORN | 0.08% | $51.34M | 0.2% |
GTIP | 0.08% | $144.83M | 0.12% |
STPZ | -0.12% | $443.63M | 0.2% |
COMT | -0.12% | $674.22M | 0.48% |
FMF | 0.14% | $154.69M | 0.95% |
FXB | -0.22% | $56.06M | 0.4% |
STIP | -0.24% | $11.52B | 0.03% |
USFR | 0.25% | $18.41B | 0.15% |
OILK | 0.27% | $66.42M | 0.69% |
SUB | 0.28% | $8.75B | 0.07% |
USL | -0.36% | $46.60M | 0.85% |
JBBB | 0.36% | $1.74B | 0.49% |
FTGC | -0.37% | $2.50B | 1.02% |
MEAR | 0.39% | $932.58M | 0.25% |
TESL | -0.42% | $16.08M | 1.2% |
LTPZ | -0.42% | $731.29M | 0.2% |
IBMR | -0.44% | $220.57M | 0.18% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BSJP | 18.99% | $993.50M | 0.43% |
JETS | 18.31% | $749.42M | 0.6% |
FDT | 18.19% | $431.27M | 0.8% |
NUKZ | 17.59% | $188.52M | 0.85% |
PID | 17.48% | $808.71M | 0.53% |
IZRL | 16.24% | $95.47M | 0.49% |
HYS | 16.18% | $1.49B | 0.56% |
HYXF | 16.14% | $184.75M | 0.35% |
BATT | 16.12% | $57.75M | 0.59% |
EWX | 15.72% | $652.41M | 0.65% |
VSS | 15.70% | $8.39B | 0.07% |
URA | 15.63% | $2.68B | 0.69% |
IBHH | 15.30% | $222.42M | 0.35% |
HYLB | 15.24% | $3.90B | 0.05% |
URNM | 15.20% | $1.22B | 0.75% |
BSJQ | 15.19% | $1.04B | 0.42% |
REMX | 15.17% | $262.64M | 0.56% |
GWX | 15.11% | $631.61M | 0.4% |
DVYE | 15.03% | $740.90M | 0.49% |
GREK | 14.81% | $184.77M | 0.57% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
SBLK | <0.01% | $1.82B | -33.98% | 13.68% |
SHW | 0.01% | $87.82B | +3.26% | 0.84% |
SYNA | 0.01% | $2.50B | -34.82% | 0.00% |
TKC | 0.01% | $5.42B | +21.01% | 3.29% |
UBER | -0.01% | $152.37B | -4.63% | 0.00% |
FDP | 0.01% | $1.48B | +21.14% | 3.40% |
TBRG | -0.01% | $411.41M | +226.84% | 0.00% |
MAR | -0.01% | $65.67B | -5.22% | 1.06% |
EZPW | -0.02% | $808.70M | +32.49% | 0.00% |
MSCI | -0.02% | $43.88B | +1.92% | 1.17% |
IRDM | -0.02% | $2.97B | +5.12% | 2.05% |
CCSI | -0.02% | $450.65M | +47.76% | 0.00% |
BARK | -0.03% | $243.13M | +13.01% | 0.00% |
WMB | 0.03% | $72.95B | +53.74% | 3.23% |
WM | 0.03% | $93.09B | +8.74% | 1.33% |
RPT | -0.03% | $136.30M | -25.65% | 8.45% |
MTG | -0.03% | $6.01B | +13.20% | 2.04% |
HAIN | 0.03% | $374.52M | -44.59% | 0.00% |
BECN | 0.04% | $7.64B | +23.42% | 0.00% |
PHG | -0.05% | $23.50B | +32.47% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
NTZ | -20.25% | $54.08M | -21.44% | 0.00% |
AVO | -15.46% | $744.83M | -10.96% | 0.00% |
PENG | -15.41% | $932.24M | -34.15% | 0.00% |
HIHO | -14.63% | $8.12M | -11.51% | 6.50% |
MGPI | -13.92% | $624.92M | -65.58% | 1.64% |
SVC | -13.59% | $434.92M | -61.33% | 16.28% |
VLO | -12.76% | $41.53B | -23.50% | 3.29% |
MPC | -12.69% | $45.39B | -28.73% | 2.37% |
LRN | -11.55% | $5.51B | +100.79% | 0.00% |
EPD | -11.16% | $73.94B | +16.24% | 6.13% |
MNR | -11.16% | $1.84B | -19.43% | 17.62% |
OFG | -11.02% | $1.82B | +11.48% | 2.64% |
IMKTA | -10.77% | $1.21B | -14.10% | 1.02% |
ODP | -10.36% | $427.30M | -72.69% | 0.00% |
USNA | -10.30% | $509.85M | -43.77% | 0.00% |
PARR | -10.27% | $775.04M | -61.75% | 0.00% |
MTRX | -10.02% | $343.15M | -4.16% | 0.00% |
LPG | -9.70% | $956.25M | -38.68% | 0.00% |
UMC | -9.61% | $17.96B | -12.05% | 6.58% |
BG | -9.60% | $10.24B | -25.29% | 3.53% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
KRRO | 36.41% | $163.46M | -80.60% | 0.00% |
VSEC | 26.24% | $2.47B | +51.85% | 0.33% |
PSQH | 26.13% | $98.27M | -53.36% | 0.00% |
TLK | 23.41% | $14.63B | -32.53% | 7.32% |
PINE | 23.39% | $245.66M | +7.87% | 6.69% |
XNCR | 22.95% | $749.71M | -51.46% | 0.00% |
AAL | 21.94% | $6.94B | -31.54% | 0.00% |
GCMG | 21.94% | $594.18M | +39.26% | 3.34% |
UAL | 21.57% | $22.60B | +45.83% | 0.00% |
VYGR | 21.45% | $186.60M | -67.93% | 0.00% |
BEP | 20.94% | $6.31B | -4.15% | 6.47% |
AUTL | 20.82% | $412.49M | -72.71% | 0.00% |
BKD | 20.76% | $1.25B | -7.12% | 0.00% |
OCUL | 20.53% | $1.17B | -15.65% | 0.00% |
DY | 20.18% | $4.41B | +9.10% | 0.00% |
APRE | 19.94% | $11.20M | -67.87% | 0.00% |
LPTX | 19.63% | $12.59M | -88.91% | 0.00% |
SNCY | 19.57% | $654.91M | -17.70% | 0.00% |
AMRC | 19.56% | $634.70M | -51.66% | 0.00% |
RLAY | 19.38% | $444.15M | -67.33% | 0.00% |